Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.06
(0.16%)
EUR 0.06
(0.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.18 Million EUR | 148.47% |
| 2022 | -4.49 Million EUR | -44.03% |
| 2021 | -3.12 Million EUR | 62.22% |
| 2020 | -8.26 Million EUR | -421.26% |
| 2019 | 2.57 Million EUR | 161.12% |
| 2018 | -4.21 Million EUR | 70.24% |
| 2017 | -14.14 Million EUR | 40.65% |
| 2016 | -23.83 Million EUR | 16.12% |
| 2015 | -28.41 Million EUR | 48.89% |
| 2014 | -55.59 Million EUR | -394.73% |
| 2013 | -11.23 Million EUR | 22.21% |
| 2012 | -14.44 Million EUR | -436.01% |
| 2011 | -2.69 Million EUR | -274.26% |
| 2010 | -720.13 Thousand EUR | 2.29% |
| 2009 | -737.02 Thousand EUR | -53.93% |
| 2008 | -478.8 Thousand EUR | -1455.66% |
| 2007 | -30.77 Thousand EUR | -9.0% |
| 2006 | -28.23 Thousand EUR | -105.16% |
| 2005 | 547.05 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.74 Million EUR | 301.19% |
| 2024 Q2 | 8.74 Million EUR | 5.41% |
| 2023 Q4 | 2.18 Million EUR | -43.41% |
| 2023 Q3 | 3.85 Million EUR | 152.85% |
| 2023 FY | 2.18 Million EUR | 148.47% |
| 2023 Q2 | -7.28 Million EUR | -104.57% |
| 2023 Q1 | -3.56 Million EUR | 20.79% |
| 2022 Q1 | -12.5 Million EUR | -300.38% |
| 2022 FY | -4.49 Million EUR | -44.03% |
| 2022 Q4 | -4.49 Million EUR | 6.04% |
| 2022 Q3 | -4.78 Million EUR | 50.89% |
| 2022 Q2 | -9.74 Million EUR | 22.05% |
| 2021 FY | -3.12 Million EUR | 62.22% |
| 2021 Q1 | -14.4 Million EUR | -74.24% |
| 2021 Q3 | -8.42 Million EUR | 39.5% |
| 2021 Q4 | -3.12 Million EUR | 62.93% |
| 2021 Q2 | -13.92 Million EUR | 3.33% |
| 2020 Q3 | -8.74 Million EUR | 28.54% |
| 2020 Q2 | -12.23 Million EUR | 3.44% |
| 2020 Q4 | -8.26 Million EUR | 5.46% |
| 2020 FY | -8.26 Million EUR | -421.26% |
| 2020 Q1 | -12.67 Million EUR | -592.42% |
| 2019 Q1 | 3.49 Million EUR | 182.99% |
| 2019 FY | 2.57 Million EUR | 161.12% |
| 2019 Q4 | 2.57 Million EUR | 5.54% |
| 2019 Q3 | 2.43 Million EUR | -38.17% |
| 2019 Q2 | 3.94 Million EUR | 12.85% |
| 2018 Q1 | -10.91 Million EUR | 22.86% |
| 2018 Q2 | -3.84 Million EUR | 64.76% |
| 2018 Q3 | -4.34 Million EUR | -12.92% |
| 2018 Q4 | -4.21 Million EUR | 3.06% |
| 2018 FY | -4.21 Million EUR | 70.24% |
| 2017 Q1 | -24.29 Million EUR | -1.94% |
| 2017 FY | -14.14 Million EUR | 40.65% |
| 2017 Q4 | -14.14 Million EUR | 0.0% |
| 2017 Q3 | -14.14 Million EUR | 27.76% |
| 2017 Q2 | -19.58 Million EUR | 19.41% |
| 2016 FY | -23.83 Million EUR | 16.12% |
| 2016 Q3 | -23.83 Million EUR | -80.25% |
| 2016 Q2 | -13.22 Million EUR | 0.0% |
| 2016 Q1 | -13.22 Million EUR | 53.47% |
| 2016 Q4 | -23.83 Million EUR | 0.0% |
| 2015 Q2 | -41.14 Million EUR | -11.08% |
| 2015 Q4 | -28.41 Million EUR | 0.0% |
| 2015 FY | -28.41 Million EUR | 48.89% |
| 2015 Q1 | -37.04 Million EUR | 33.38% |
| 2015 Q3 | -28.41 Million EUR | 30.94% |
| 2014 Q3 | -55.59 Million EUR | -193.22% |
| 2014 Q4 | -55.59 Million EUR | 0.0% |
| 2014 Q2 | -18.96 Million EUR | -53.92% |
| 2014 FY | -55.59 Million EUR | -394.73% |
| 2014 Q1 | -12.31 Million EUR | -9.62% |
| 2013 Q4 | -11.23 Million EUR | -189.6% |
| 2013 FY | -11.23 Million EUR | 22.21% |
| 2013 Q3 | -3.88 Million EUR | 67.14% |
| 2013 Q2 | -11.8 Million EUR | -78.02% |
| 2013 Q1 | -6.63 Million EUR | 54.09% |
| 2012 FY | -14.44 Million EUR | -436.01% |
| 2012 Q2 | -5.76 Million EUR | 0.0% |
| 2012 Q4 | -14.44 Million EUR | 0.0% |
| 2011 Q4 | -2.69 Million EUR | 0.0% |
| 2011 FY | -2.69 Million EUR | -274.26% |
| 2011 Q2 | 2.23 Million EUR | 0.0% |
| 2010 FY | -720.13 Thousand EUR | 2.29% |
| 2010 Q4 | -720.13 Thousand EUR | 0.0% |
| 2010 Q2 | 1.41 Million EUR | 0.0% |
| 2009 Q4 | -737.02 Thousand EUR | 0.0% |
| 2009 FY | -737.02 Thousand EUR | -53.93% |
| 2008 FY | -478.8 Thousand EUR | -1455.66% |
| 2007 FY | -30.77 Thousand EUR | -9.0% |
| 2006 FY | -28.23 Thousand EUR | -105.16% |
| 2005 FY | 547.05 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 405.322% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 101.11% |
| Adocia SA | 127 Thousand EUR | -1616.535% |
| Aelis Farma SA | -16.19 Million EUR | 113.463% |
| Biophytis S.A. | 2.7 Million EUR | 19.349% |
| Advicenne S.A. | 12.17 Million EUR | 82.094% |
| genOway Société anonyme | 2.97 Million EUR | 26.673% |
| IntegraGen SA | -709.74 Thousand EUR | 407.151% |
| Medesis Pharma S.A. | 1.15 Million EUR | -88.221% |
| Neovacs S.A. | -237.08 Thousand EUR | 1019.494% |
| NFL Biosciences SA | -2.27 Million EUR | 195.788% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 49.96% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 362.477% |
| Sensorion SA | 1.37 Million EUR | -58.175% |
| Theranexus Société Anonyme | 2.44 Million EUR | 10.808% |
| TME Pharma N.V. | -1.07 Million EUR | 302.039% |
| Valbiotis SA | -18.13 Million EUR | 112.018% |
| TheraVet SA | 12.78 Thousand EUR | -16951.232% |
| DBV Technologies S.A. | -114.95 Million USD | 101.896% |
| Genfit S.A. | -7.61 Million EUR | 128.643% |
| GeNeuro SA | 5.91 Million EUR | 63.116% |
| Innate Pharma S.A. | -30.71 Million EUR | 107.098% |
| Inventiva S.A. | 10.48 Million EUR | 79.216% |
| MaaT Pharma SA | -10.2 Million EUR | 121.362% |
| MedinCell S.A. | 39.5 Million EUR | 94.481% |
| Nanobiotix S.A. | -24.71 Million EUR | 108.819% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 91.964% |
| Poxel S.A. | 44.55 Million EUR | 95.108% |
| GenSight Biologics S.A. | 16.29 Million EUR | 86.621% |
| Transgene SA | -14.4 Million EUR | 115.129% |
| Valneva SE | 82.73 Million EUR | 97.365% |